J Gregory Cairncross

Title: J Gregory Cairncross: Innovator in Cancer Research

Introduction

J Gregory Cairncross is a prominent inventor based in London, Canada. He has made significant contributions to the field of cancer research, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work has advanced the understanding and treatment of melanoma and astrocytoma.

Latest Patents

Cairncross's latest patents include groundbreaking discoveries in the realm of monoclonal antibodies. One of his notable patents focuses on monoclonal antibodies against melanocytes. This invention recognizes differentiation antigens on melanocytes and melanoma cells at various stages of differentiation. A system of classification based on these antigens is proposed, along with their application in the diagnosis and treatment of melanoma. Another significant patent involves the cell surface antigens of human astrocytoma. This patent describes a method for forming an antibody-producing hybridoma cell line by fusing a myeloma cell line with splenocytes derived from BALB/c mice immunized with human astrocytoma tumor cells. The hybridoma cell line formed generates monoclonal antibodies, and a method for phenotyping astrocytoma tumor cells is also provided.

Career Highlights

Cairncross is affiliated with the Sloan-Kettering Institute for Cancer Research, where he continues to contribute to innovative cancer research. His work has been instrumental in advancing therapeutic strategies for cancer treatment.

Collaborations

Some of his notable coworkers include Anthony P Albino and Alan N Houghton, who have collaborated with him on various research projects.

Conclusion

J Gregory Cairncross is a distinguished inventor whose work in cancer research has led to significant advancements in the understanding and treatment of melanoma and astrocytoma. His contributions continue to impact the field positively.